Seres Therapeutics

Our CEO Eric Shaff will be participating in a fireside chat at the upcoming Piper Sandler Annual Healthcare Conference on December 3rd. Can't make it to the event? We'll also be streamlining?a live webcast through our website and will post the recording afterwards. Read the release: https://lnkd.in/gb7wJ_-q

Today we reported our Q3 financial results and provided business updates, including planned next steps for SER-155 following encouraging Phase 1b data in allo-HSCT patients. Read more in the full release: https://lnkd.in/eMfU2T7e

Today we’re pleased to share Cohort 2 data from our Phase 1b study evaluating SER-155 in patients undergoing allo-HSCT. Read the full release here: https://lnkd.in/ekKD-Tqf --- Summary of Cohort 2 Results (through day 100 post HSCT) - SER-155 was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia - SER-155 demonstrated a generally well tolerated safety profile and had confirmed drug bacteria strain engraftment; no treatment-related serious adverse events were observed - Seres will seek Breakthrough Therapy designation from the FDA and discuss plans to advance development of SER-155 in allo-HSCT.

Today we're excited to announce that we've signed the VOWST asset purchase agreement with Nestlé. The completion of the transaction, which is subject to Seres’ shareholder approval and other customary conditions, is expected to occur in the next 90 days.? ? Read the full release: https://lnkd.in/eZmJuF7y

Our team had a great time at Friday’s #BioBall event, sponsored by Special Olympics Massachusetts. Not only was it fun to get together for the afternoon, but we helped raise money to support our local #SpecialOlympics athletes! Check out the Special Olympics Massachusetts website to learn about the organization’s mission to support over 14,000 athletes with intellectual disabilities:?https://lnkd.in/e48swYSF

Today we announced an exciting new chapter in our story as pioneers of microbiome therapeutics: an agreement with long-time partner Nestlé Health Science to acquire full rights to Vowst. This will allow us to focus on pursuing our mission of transforming the lives of patients by developing revolutionary medicines. https://lnkd.in/gGzxKtek

Seres is excited to present new preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study in hematopoietic stem cell transplant patients at #ASCO24 in Chicago. Join us at the poster session on June 3rd at 9am CDT. Learn more: https://lnkd.in/e7wYXuWE?

We are thrilled to announce that Matthew Henn, Seres CSO, will be giving a Codex Talk alongside other biotech leaders during next week's Codex World's Top 50 Innovators event:?https://lnkd.in/dqMRuE_F Matt's presentation will be on May 9th at 9am, titled "How can we harness millions of years of coevolution between microbial and human cells to impact health?" He'll be discussing the potential and promise of microbiome therapeutics to treat a broad spectrum of infectious, inflammatory, immunological, metabolic, and neurological diseases. Following a series of presentations, Matt and fellow panelists will have a broader discussion and Q&A. We hope to see you there!

Seres is excited to present preliminary data on investigational #microbiome therapeutic SER-155 from the first cohort (open-label) of our Phase 1b study at #EBMT24 in Glasgow. Join us at the poster session on April 15th at 6pm GMT+1. Learn more: https://lnkd.in/esemjF6A?

We're excited to share that Seres Therapeutics has completed patient enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT) patients. This milestone brings us closer to potentially revolutionizing the approach to enteric-derived infections and bloodstream infections post-transplantation, helping to prevent complications such as Graft vs. Host Disease (GvHD). ? SER-155, an orally administered consortium of bacteria, aims to mitigate infections—a leading cause of mortality in immunocompromised patients like those undergoing Allo HSCT. With enrollment complete, we expect a clinical data readout by the end of Q3 2024. ? Read the full release here:?https://lnkd.in/e2jNaHS3 ? Stay tuned for updates as we continue to advance SER-155 and explore its potential in other high-prevalence patient populations.?